Related by context. All words. (Click for frequent words.) 69 AEG# 68 axitinib 68 ganetespib 68 tanespimycin 67 Amrubicin 67 Phase Ib study 67 XL# [003] 67 Sym# 67 MEK inhibitor 67 elotuzumab 67 OXi# 67 EOquin 66 Phenoptin 66 EOquin TM 66 phase Ib 66 perifosine 66 eniluracil 66 alvespimycin 66 Phase Ib II 66 Aflibercept 66 HGS ETR1 66 JAK inhibitor 66 PRT# 66 Phase Ib 66 Carfilzomib 66 HGS# 66 PS# [001] 66 dose escalation trial 66 pertuzumab 65 BAY #-# 65 RG# [001] 65 HuMax EGFr 65 HuMax CD# 65 Tamibarotene 65 fipamezole 65 Archexin 65 dose escalation Phase 65 polymerase inhibitor 65 AZD# 65 PSN# [002] 65 Aplidin 65 ozarelix 65 PEG Interferon lambda 65 INCB# [001] 64 Perifosine 64 AP# [003] 64 Dapagliflozin 64 ATL# [002] 64 phase IIb clinical 64 Pimavanserin 64 FTY# 64 SCH # 64 Amigal 64 LY# [002] 64 Traficet EN 64 Phase Ib clinical 64 XmAb# 64 sorafenib Nexavar 64 GSK# [001] 64 Panzem R NCD 64 ATL# [001] 64 AQ4N 64 AEGR 64 LAF# 64 oral prodrug 64 fosbretabulin 64 otelixizumab 64 orally bioavailable 64 HuMax CD4 64 rNAPc2 64 Initiated Phase 64 ISIS # 64 HGS ETR2 64 placebo controlled Phase 64 YONDELIS 64 phase IIa clinical 64 carfilzomib 64 PDE4 inhibitor 64 MGd 64 Laquinimod 64 Bezielle 64 methylnaltrexone 64 Phase 2b study 63 TELINTRA 63 dose cohorts 63 teriflunomide 63 enzastaurin 63 neratinib 63 PI3K inhibitor 63 IMC A# 63 MDV# 63 DB# [003] 63 SAR# [004] 63 dacetuzumab 63 BIBW 63 IMGN# 63 PSMA ADC 63 palonosetron 63 nitric oxide donating prostaglandin 63 amrubicin 63 teduglutide 63 CCX# 63 Phase 2b trial 63 pradefovir 63 Aplidin R 63 anticancer agent 63 lintuzumab 63 Dacogen injection 63 Nexavar ® 63 Cetrorelix 63 MT# MEDI 63 CBLC# 63 CYT# 63 investigational compound 63 mapatumumab 63 Plicera 63 PXD# 63 phase IIa 63 KRN# 63 registrational trial 63 ONX 63 SAR# [002] 63 preclinically 63 huC# DM4 63 Serdaxin 63 PEG SN# 63 dose escalation 63 histone deacetylase HDAC inhibitor 63 TG# [003] 63 atacicept 62 radiation sensitizer 62 bardoxolone 62 Azedra 62 MGCD# [001] 62 forodesine 62 ancrod 62 dimebon 62 Safinamide 62 ongoing Phase 1b 62 SRT# [003] 62 pan HDAC inhibitor 62 GAMMAGARD 62 mertansine 62 liposomal formulation 62 EndoTAG TM -1 62 PHX# 62 lubiprostone 62 cilengitide 62 laquinimod 62 R roscovitine 62 bendamustine 62 bevacizumab Avastin ® 62 ASA# 62 Tanespimycin 62 XL# XL# XL# 62 TELCYTA 62 Phase 1b 62 R#/MEM # 62 Bortezomib 62 OncoVEX GM CSF 62 Apaziquone 62 Zerenex 62 RhuDex ® 62 pharmacokinetic profile 62 TYKERB 62 Tolvaptan 62 Cloretazine ® 62 sorafenib tablets 62 phase IIb 62 Nanobody 62 ENMD # 62 Mipomersen 62 ospemifene 62 nucleoside analog 62 blinatumomab 62 VEGF Trap 62 tamibarotene 62 ELND# 62 multicenter Phase 62 eprotirome 62 apremilast 62 obatoclax 62 metaglidasen 62 dose escalation clinical 62 mTOR inhibitor 62 Randomized Phase 62 GRN#L 62 fostamatinib 62 generation purine nucleoside 62 receptor tyrosine kinase inhibitor 62 BAL# [002] 62 vascular disrupting agent 62 angiogenesis inhibitor 62 Ambrisentan 62 volociximab 62 galiximab 62 INCB# [002] 62 HDAC Inhibitor 62 Pivotal Phase 62 cannabinor 62 CCR5 antagonist 62 adecatumumab 62 CEQ# 61 DU #b 61 Allovectin 7 ® 61 pitavastatin 61 KNS # 61 ocrelizumab 61 sapacitabine 61 evaluating tivozanib 61 torezolid phosphate 61 Sapacitabine 61 vismodegib 61 RGB # 61 IPX# 61 celgosivir 61 pomalidomide 61 TBC# 61 PRX# 61 Alocrest 61 anticancer compound 61 HIV integrase inhibitor 61 Ceflatonin 61 GFT# 61 pharmacokinetic PK study 61 Initiate Phase 61 Dasatinib 61 TACI Ig 61 SUTENT 61 PEG PAL 61 IDX# 61 ARRY 61 DAVANAT 61 INCB# [003] 61 Lacosamide 61 BNC# 61 Phase IIb trials 61 ularitide 61 Phase #b/#a 61 Allovectin 7 61 Pivotal Phase III 61 relapsed multiple myeloma 61 Phase 1b trial 61 lixisenatide 61 nab paclitaxel 61 Posiphen 61 Alzhemed TM 61 desvenlafaxine succinate 61 Rebif ® 61 preclinical efficacy 61 Ophena TM 61 Pafuramidine 61 Azacitidine 61 sulodexide 61 AEZS 61 randomized controlled Phase 61 Lu AA# 61 TREANDA 61 Phase 2a trial 61 decitabine 61 NGX# 61 BRAF inhibitor 61 Phase IIa clinical 61 DP b# 61 PD LID 61 bendamustine HCl 61 belinostat 61 Targretin 61 CA4P 61 MAP# 61 ixabepilone 61 CRx 61 tivozanib 61 sodium glucose cotransporter 61 Bicifadine 61 sunitinib malate 61 Clevudine 61 epothilone 61 trastuzumab DM1 61 IAP inhibitor 61 entinostat 61 cathepsin K inhibitor 61 Phase Ib clinical trials 61 nitazoxanide 61 NVA# 61 GW# [003] 61 aflibercept 61 tocilizumab 61 tezampanel 61 daclizumab 61 tremelimumab 61 Guanilib 61 non nucleoside inhibitor 61 MEK inhibitors 61 dasatinib Sprycel ® 61 ELACYT 61 Naproxcinod 61 Triolex 61 CLORETAZINE TM VNP#M 61 placebo controlled Phase III 61 Imprime PGG 61 6R BH4 61 active comparator 61 Insegia 61 Allovectin 7 R 60 HCD# [002] 60 oral ridaforolimus 60 Onalta 60 NOX E# 60 CoFactor 60 placebo controlled clinical 60 Kinase Inhibitor 60 INT# [002] 60 ThermoDox R 60 Neulasta ® 60 lumiliximab 60 docetaxel Taxotere ® 60 Tyrima 60 Tasimelteon 60 PNP inhibitor 60 oncology indications 60 LUX Lung 60 BRIM2 60 NXL# 60 Amplimexon 60 PrevOnco 60 Xanafide 60 vemurafenib 60 selective androgen receptor modulator 60 Akt inhibitor 60 trabectedin 60 Debio 60 HER2 positive metastatic breast 60 FOLOTYN 60 Phase IIa trials 60 Hsp# inhibitor 60 huN# DM1 60 Velcade bortezomib 60 CR# vcMMAE 60 Phase #/#a 60 deforolimus 60 posaconazole 60 EDEMA3 60 TG# [001] 60 somatostatin analogue 60 BRIM3 60 cediranib 60 ascending dose 60 PEG IFN 60 NKTR 60 subcutaneous formulation 60 CCX# B 60 phase IIb trial 60 Zybrestat 60 Tarceva TM 60 pharmacokinetics PK 60 Zenvia Phase III 60 Vilazodone 60 mGluR5 negative 60 HCV SPRINT 60 PEGylated Fab fragment 60 TOCOSOL Paclitaxel 60 Phase 1a clinical 60 HuLuc# 60 RhuDex 60 MORAb 60 Panzem NCD 60 AZILECT R 60 sunitinib 60 Onconase 60 CCR5 inhibitor 60 seliciclib CYC# 60 GLPG# 60 ulimorelin 60 glatiramer acetate 60 mipomersen 60 temsirolimus 60 iSONEP 60 Lubiprostone 60 Betaferon ® 60 pharmacodynamics 60 Vandetanib 60 multicenter Phase III 60 Aurora kinase inhibitor 60 SNT MC# 60 darapladib 60 LY# [003] 60 dexpramipexole 60 Cloretazine 60 ocular hypertension 60 Annamycin 60 vorinostat 60 AVE# 60 ruxolitinib 60 Hsp# Inhibitor 60 Nippon Kayaku 60 ADVEXIN 60 Phase IIa trial 60 clevudine 60 Asentar 60 ofatumumab 60 FOLOTYN ® 60 Cannabinor 60 depsipeptide 60 docetaxel Taxotere R 60 teplizumab 60 Vitaxin 60 Exelixis compounds 60 Blinatumomab 60 BMS # 60 favorable pharmacokinetic profile 60 APOPTONE 60 Androxal TM 60 ISENTRESS 60 ZOLINZA 60 selective modulator 60 adecatumumab MT# 60 Ocrelizumab 60 orally administered inhibitor 60 Chemophase 60 laninamivir 60 TRO# 60 proteasome inhibitor 60 ATL/TV# 60 tarenflurbil 60 OMP #M# 60 Anavex #-# 60 MAGE A3 ASCI 60 PRTX 60 albinterferon alfa 2b 60 Proxinium TM 60 AAG geldanamycin analog 60 Teysuno 60 Apoptone 60 gefitinib Iressa 60 voreloxin 60 RH1 60 HSP# inhibitor 59 ZYBRESTAT 59 MetMAb 59 DDP# 59 DermaVir Patch 59 kinase inhibitor 59 TASQ 59 Zalbin 59 dalbavancin 59 Raptiva ® 59 investigational oral 59 Pazopanib 59 Phase 2a clinical 59 XL# XL# XL# XL# 59 eltrombopag 59 romidepsin 59 perampanel 59 safinamide 59 sorafenib 59 crizotinib PF # 59 Aurora kinase 59 non nucleoside 59 PDX pralatrexate 59 AZILECT ® 59 Pradefovir 59 phase IIb study 59 dosing cohort 59 Preclinical studies suggest 59 Fx #A 59 sorafenib Nexavar ® 59 Aurora Kinase 59 AzaSite Plus 59 Phase #b/#a trial 59 antisense drug 59 investigational humanized monoclonal antibody 59 ORMD 59 GLP toxicology studies 59 Daclizumab 59 metastatic RCC 59 aleglitazar 59 Belinostat 59 pharmacodynamic 59 Glufosfamide 59 GATTEX ® 59 Fibrillex TM 59 Zolinza 59 dose cohort 59 dabigatran etexilate 59 IMC #B 59 Irinotecan 59 relapsed refractory multiple myeloma 59 thymalfasin 59 gemcitabine Gemzar ® 59 telbivudine 59 ALGRX 59 Excellarate 59 Phase 1b clinical 59 ocular formulation 59 metastatic renal cell carcinoma 59 T DM1 59 Darinaparsin 59 ThermoDox ® 59 Cloretazine R VNP#M 59 OvaRex ® MAb 59 Fulvestrant 59 midstage clinical 59 Azixa 59 cetrorelix 59 virus HCV protease inhibitor 59 Tofacitinib 59 latrepirdine 59 GALNS 59 Diamyd ® 59 PLX# 59 Spiegelmer ® 59 pharmacokinetics 59 LymphoStat B 59 IAP inhibitors 59 Oral NKTR 59 Hedgehog pathway inhibitor 59 dose escalation study 59 R#/MEM 59 GV# [001] 59 JAK1 59 vidofludimus 59 CXB# 59 ZD# [001] 59 Phase 2b clinical trials 59 bortezomib Velcade 59 ASONEP 59 muraglitazar 59 timolol 59 Alfimeprase 59 Neuradiab 59 tesmilifene 59 ZYBRESTAT fosbretabulin 59 Kissei Pharmaceutical 59 XL# XL# 59 CUDC 59 Trofex 59 CIMZIA TM 59 CXA 59 Aclidinium 59 IND enabling 59 iniparib 59 Luteinizing Hormone Releasing Hormone 59 vicriviroc 59 inhibitor RG# 59 Copegus ribavirin 59 CB2 selective receptor agonist 59 pharmacodynamic properties 59 multi kinase inhibitor 59 Tezampanel 59 optimal dosing regimen 59 Synavive 59 Omacetaxine 59 Arranon 59 novel VDA molecule 59 Saxagliptin 59 olaparib 59 intravenous dosing 59 brivaracetam 59 Golimumab 59 ACTEMRA 59 PROMACTA 59 dirucotide 59 QLT# 59 APTIVUS r 59 renin inhibitor 59 EP #R 59 Desmoteplase 59 unoprostone isopropyl 59 HDAC inhibitor 59 phase Ib clinical 59 Phase IIIb clinical 59 Trastuzumab DM1 59 EndoTAG 59 ZACTIMA 59 Pertuzumab 59 PKC# 59 Panzem R 59 Enzastaurin 59 Rasagiline 59 goserelin 59 Virulizin ® 59 atrasentan 59 ALKS 59 GAMMAGARD LIQUID 59 betrixaban 59 preclinical 59 TORISEL 59 IRESSA 59 ProSavin 59 Vascular Disrupting Agent 59 CIMZIA ™ 59 INC# 59 tyrosine kinase inhibitor 59 Elesclomol 59 pharmacokinetic profiles 59 ORENCIA ® 59 TMC# [002] 59 systemically administered 59 oral deforolimus 59 sirolimus 59 anti leukemic 59 Darusentan 59 novel anticancer 59 registrational studies 59 peginesatide 59 HCV protease inhibitor 59 albiglutide 59 Cladribine Tablets 59 Exelixis XL# 59 SPC# [001] 59 trastuzumab DM1 T DM1 59 Iloperidone 59 #D#C# 59 TEMODAL 59 ADX# 59 regadenoson 59 antiplatelet agent 59 blinded randomized placebo controlled 59 ADP receptor antagonist 59 pharmacokinetic PK 59 XOMA 3AB 59 erlotinib Tarceva ® 59 farletuzumab 59 generation FBPase inhibitor 59 Elagolix 59 mitogen activated ERK kinase 59 PCK# 59 rALLy trial 59 confirmatory Phase III 58 Phase IIIb 58 NP2 Enkephalin 58 registrational 58 Epratuzumab 58 ALN TTR# 58 Troxatyl 58 PEG INTRON 58 alvimopan 58 lorvotuzumab mertansine 58 CANCIDAS 58 Kahalalide F 58 Enhanze Technology 58 SUTENT ® 58 TH# [003] 58 dosage regimens 58 RAPAFLO 58 pharmacodynamic PD 58 PREOS 58 Syncria 58 MNTX 58 Silodosin 58 BCX# 58 KSP inhibitor 58 SPP# [001] 58 small molecule Hedgehog 58 NLX P# 58 Ixabepilone 58 Phase III placebo controlled 58 cangrelor 58 edoxaban 58 Genasense ® 58 JAK inhibitors 58 class mGluR5 inhibitor 58 GLYX 58 fluticasone furoate 58 Atiprimod 58 Meets Primary Endpoint 58 rHuPH# 58 IL# PE#QQR 58 Cyclooxygenase Inhibiting Nitric Oxide 58 oral salmon calcitonin 58 Prostate AdenoCarcinoma Treatment 58 viral kinetics 58 Pharmacokinetics PK 58 seliciclib 58 perifosine KRX 58 pegylated interferons 58 silodosin 58 diabetic neuropathic pain 58 intranasal formulation 58 ritonavir boosted danoprevir 58 CBLB# 58 PEGylated anti 58 tenofovir emtricitabine 58 JANUVIA 58 IFN α 58 Tarvacin 58 pegylated liposomal doxorubicin 58 cinacalcet HCl 58 recurrent NSCLC 58 Telcyta 58 dose limiting toxicities 58 PEG interferon 58 Phase III Clinical Trial 58 Phase IIb clinical trials 58 ORENCIA R 58 mGluR5 NAM 58 GSK# [002] 58 CYT# potent vascular disrupting 58 tolerated dose MTD 58 XYOTAX TM 58 INGN 58 capecitabine Xeloda 58 Antiviral Activity 58 VELCADE melphalan 58 orally dosed 58 AVONEX ® 58 hematological malignancies 58 Multimeric 58 reslizumab 58 pharmacodynamic effects 58 TYGACIL 58 riociguat 58 talactoferrin 58 clofarabine 58 Ecallantide 58 satraplatin 58 PREOS R 58 Janus Kinase 58 lintuzumab SGN 58 LIVALO 58 gefitinib 58 Keryx Biopharma 58 Teriflunomide 58 non nucleoside HCV 58 febuxostat 58 ALN TTR 58 Azedra TM 58 Ceflatonin R 58 refractory CLL 58 TRC# 58 Melphalan 58 selective kinase inhibitor 58 multicenter randomized placebo controlled 58 Phase 2a 58 elagolix 58 Cimzia ® 58 dyskinesia PD LID 58 diarrhea predominant irritable 58 TKM ApoB 58 YONDELIS R 58 Avanafil 58 Voreloxin 58 phase 2a 58 HQK 58 mg kg BID 58 investigational compounds 58 Phase IIb trial 58 APTIVUS 58 Omacetaxine mepesuccinate 58 MGCD# [002] 58 VQD 58 Phase 2b clinical 58 rFVIIIFc 58 methylnaltrexone bromide 58 vandetanib 58 Dalbavancin 58 apaziquone 58 Behcet uveitis 58 budesonide MMX 58 nonclinical studies 58 CG# [003] 58 GED aPC 58 adenosine injection 58 rFIXFc 58 BENLYSTA ® 58 Tocilizumab 58 Prodarsan ® 58 azacitidine 58 TRX1 58 Ziopharm 58 4SC 58 Ixempra 58 pharmacokinetic characteristics 58 MT#/MEDI-# 58 diabetic nephropathy 58 Interferon alpha 58 oral proteasome inhibitor 58 PI3K inhibitors 58 custirsen 58 Neulasta R 58 Tarvacin TM 58 Phase IIb III 58 Romidepsin 58 EZN 58 aurora kinase 58 bavituximab 58 MYDICAR ® 58 zileuton 58 multicenter Phase II 58 PROSTVAC TM 58 TREDAPTIVE 58 cytokine refractory 58 APPRAISE 58 luteinizing hormone releasing 58 Phase III Pivotal 58 IMA# 58 MBP# [001] 58 BiTE antibody 58 Xeloda ® 58 Vaprisol 58 LEP ETU 58 tubulin inhibitor 58 carboplatin paclitaxel 58 GRN# 58 lurasidone 58 dirucotide MBP# 58 thalidomide Thalomid 58 Vidaza azacitidine 58 Icatibant 58 PRX # 58 zalutumumab 58 RDEA# 58 isoform selective 58 synthetic retinoid 58 Phase IIb clinical 58 pharmacokinetics pharmacodynamics 58 Phase #b/#a clinical 58 ILUVIEN ® 58 RRMS patients 58 Nimotuzumab 58 Prograf ® 58 LB# [003] 58 docetaxel chemotherapy 58 azilsartan medoxomil 58 ximelagatran 58 ARQ 58 EURIDIS 58 liposomal doxorubicin 58 Anticalin R 58 regorafenib 58 mixed dyslipidemia 58 lacosamide 58 prostate cancer AIPC 58 Lodotra 58 Afatinib 58 Genz # 58 Cotara 58 BZL# 58 ThermoDox 58 oral antiviral 58 Prestara 58 tolerability pharmacokinetics 58 histone deacetylase inhibitor 58 Nexavar sorafenib 58 LHRH antagonist 58 Catena ® 58 BENICAR HCT 58 Tesetaxel 57 XL# SAR# 57 safety tolerability pharmacokinetic 57 CD4 monoclonal antibody 57 sunitinib Sutent 57 severe gastroparesis 57 davunetide intranasal AL 57 elacytarabine 57 MAXY alpha 57 CINOD 57 initiate Phase 1b 57 DPP4 inhibitor 57 Zoraxel 57 Cethromycin 57 Clolar ® 57 interferon gamma 1b 57 ALN VSP 57 pafuramidine 57 PF # [002] 57 Universal Flu Vaccine 57 secondary efficacy endpoints 57 Phase III randomized controlled 57 CRLX# 57 Phase 2b Clinical Trial 57 Hematide 57 ceftaroline 57 Radezolid 57 Phase IIa clinical trials 57 Erlotinib 57 Combo Stent 57 Bevacizumab 57 IIa trial 57 Capesaris 57 oral Xeloda 57 DXL# 57 Ozarelix 57 biliary tract cancer 57 Elvitegravir 57 alpha 2b 57 Degarelix 57 subcutaneously administered 57 rhMBL 57 Anticalin 57 humanized anti 57 terlipressin 57 ACTEMRA TM 57 castrate resistant prostate cancer 57 PrevOnco ™ 57 plasma kallikrein inhibitor 57 Sorafenib 57 tezampanel NGX# 57 partial agonist 57 CDK inhibitor 57 omecamtiv mecarbil 57 BARACLUDE R 57 GSK # 57 JZP 57 AZOR 57 CERE 57 SUCCEED trial 57 dipeptidyl peptidase 4 57 Stimuvax R 57 UVIDEM 57 baminercept 57 Tavocept 57 latanoprost 57 raltegravir 57 elesclomol 57 multiple ascending dose 57 VEGF receptor 57 SARMs 57 HDACi 57 TKB# 57 BMS# 57 sitagliptin 57 subcutaneous PRO 57 ritonavir boosted 57 rhIGFBP 3 57 Exherin TM 57 TO AVOID PREGNANCY WHILE 57 beta2 agonist 57 VAPRISOL 57 angiotensin receptor blocker ARB 57 drug conjugate 57 M Vax 57 ARRY # 57 FRDA 57 tesetaxel 57 zanolimumab 57 μg dose 57 fenofibric acid 57 SB# ONX 57 eritoran 57 Dabigatran etexilate 57 Evoltra ® 57 glucokinase activator 57 ascending doses 57 Dual Opioid 57 bortezomib Velcade R 57 Stedivaze 57 Ofatumumab 57 receptor inhibitor 57 oral Azacitidine 57 Ceflatonin ® 57 alagebrium 57 targeted radiotherapeutic 57 thiazolidinediones TZDs 57 integrase inhibitor 57 visilizumab 57 Phase IIa 57 ceftazidime 57 Pegasys ® 57 cetuximab Erbitux R 57 compound AEZS 57 ACZ# 57 FLT3 57 Phase III clinical 57 irbesartan 57 treatment naive genotype 57 Pemetrexed 57 JP-#/fipamezole 57 preclinical studies 57 EGS# 57 Anthim 57 aclidinium bromide 57 Pivotal Trial 57 Kepivance 57 palifosfamide Zymafos TM 57 KB# [002] 57 Menerba 57 sitaxsentan 57 JAK2 inhibitor 57 denufosol 57 midstage trials 57 lomitapide 57 ridaforolimus 57 aflibercept VEGF Trap 57 Nanobody ® 57 figitumumab 57 bexarotene 57 myeloproliferative disorders 57 omacetaxine mepesuccinate 57 DCCR 57 CD3 monoclonal antibody 57 Cloretazine R 57 indibulin 57 TAFA# 57 ISEL 57 Phase IIb Trial 57 TASKi2 57 Aptivus ®